Impact of dose frequency on compliance and health outcomes: a literature review (1966–2006)

References

• Heerdink ER, Urquhart J. Leufkens HG. Changes in prescribed drug doses after market introduction. Pharmacoepidemiol. Drug Saf.11(6), 447–453 (2002).
   PubMed Web of Science ®Google Scholar
• Vrijens B, Urquhart J. Patient adherence to prescribed antimicrobial drug dosing regimens. J. Antimicrob. Chemother.55(5), 616–627 (2005).
   PubMed Web of Science ®Google Scholar
• Babazono A, Miyazaki M, Imatoh T et al. Effects of the increase in co-payments from 20 to 30 percent on the compliance rate of patients with hypertension or diabetes mellitus in the employed health insurance system. Int. J. Technol. Assess. Health Care21(2), 228–233 (2005).
   Google Scholar
• Hinkin CH, Castellon SA, Durvasula RS et al. Medication adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity. Neurology59(12), 1944–1950 (2002).
   PubMed Web of Science ®Google Scholar
• Rothenbacher D, Ruter G, Brenner H. Prognostic value of physicians’ assessment of compliance regarding all-cause mortality in patients with Type 2 diabetes: primary care follow-up study. BMC Fam. Pract.7, 42 (2006).
   PubMedGoogle Scholar
• Kogut SJ, Andrade SE, Willey C, Larrat EP. Nonadherence as a predictor of antidiabetic drug therapy intensification (augmentation). Pharmacoepidemiol. Drug Saf.13(9), 591–598 (2004).
   Google Scholar
• Elliott RA, Barber N, Horne R. Cost-effectiveness of adherence-enhancing interventions: a quality assessment of the evidence. Ann. Pharmacother.39(3), 508–515 (2005).
   PubMed Web of Science ®Google Scholar
• Kyngas H, Lahdenpera T. Compliance of patients with hypertension and associated factors. J. Adv. Nurs.29(4), 832–839 (1999).
   PubMed Web of Science ®Google Scholar
• Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr. Bull.23, 637–651 (1997).
   PubMed Web of Science ®Google Scholar
• Perkins DO. Predictors of noncompliance in patients with schizophrenia. J. Clin. Psychiatry63(12), 1121–1128 (2002).
   PubMed Web of Science ®Google Scholar
• Sclar DA, Robison LM, Skaer TL, Dickson WM, Kozma CM, Reeder CE. Sulfonylurea pharmacotherapy regimen adherence in a Medicaid population: influence of age, gender, and race. Diabetes Edu.25(4), 531–532, 535, 537–538 (1999).
   PubMed Web of Science ®Google Scholar
• Wertheimer A, Santella T, Finestone A, Levy R. Drug delivery systems improve pharmaceutical profile and facilitate medication adherence. Adv. Ther.22(6), 559–577 (2005).
   PubMed Web of Science ®Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin. Ther.23, 1296–1310 (2001).
   PubMed Web of Science ®Google Scholar
• Richter A, Anton SE, Koch P, Dennett SL. The impact of reducing dose frequency on health outcomes. Clin. Ther.25(8), 2307–2335 (2003).
   PubMed Web of Science ®Google Scholar
• Morris AD. Addressing dosing frequency in diabetes: a simple approach to improving adherence to therapy and clinical outcomes. Diabetes Educ.29(3), 440–446, 448, 450–453 (2003).
   PubMed Web of Science ®Google Scholar
• Porter A. Daily regimen and compliance with treatment: literature before 1980 should not have been ignored. Br. Med. J.324, 425 (2002).
   Google Scholar
• Andrejak M, Genes N, Vaur L, Poncelet P, Clerson P, Carre A. Electronic pill boxes in the evaluation of antihypertensive compliance: comparison of once daily versus twice daily regimen. Am. J. Hypertens.13, 184–190 (2000).
   PubMed Web of Science ®Google Scholar
• Boissel JP, Meillard O, Perrin-Fayolle E et al. Comparison between a bid and a tid regimen: improved compliance with no improved antihypertensive effect. The EOL Research Group. Eur. J. Clin. Pharmacol.50(1–2), 63–67 (1996).
   Google Scholar
• Brun J. Patient compliance with once-daily and twice-daily oral formulations of 5-isosorbide mononitrate: a comparative study. J. Int. Med. Res.22(5), 266–272 (1994).
   PubMed Web of Science ®Google Scholar
• Eisen S, Miller D, Woodward R, Spitzangel E, Pryzbeck T. The effect of prescribed daily dose frequency on patient medication compliance. Arch. Intern. Med.150(9), 1881–1884 (1990).
   PubMed Web of Science ®Google Scholar
• Gabriel M, Gagnon J, Bryan C. Improved patient compliance through use of a daily drug reminder chart. Am. J. Public Health67(10), 968–969 (1977).
   PubMed Web of Science ®Google Scholar
• Leenen FH, Wilson TW, Bolli P et al. Patterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: a randomized clinical trial using electronic monitoring. Can. J. Cardiol.13(10), 914–920 (1997).
   PubMed Web of Science ®Google Scholar
• Mengden T, Binswanger B, Spuhler T, Weisser B, Vetter W. The use of self-measured blood pressure determinations in assessing dynamics of drug compliance in a study with amlodipine once a day, morning versus evening. J. Hypertens.11(12), 1403–1411 (1993).
   PubMed Web of Science ®Google Scholar
• Rindone JP, Hiller D, Arriola G. A comparison of fluvastatin 40 mg every other day versus 20 mg every day in patients with hypercholesterolemia. Pharmacother.18(4), 836–839 (1998).
   Google Scholar
• Sramek JJ, Cutler NR, Seifert RD, Luna AD. Compliance in hypertension: daily v. twice daily. Am. J. Hypertens.6, 1063 (1993).
   Google Scholar
• Detry JM, Block P, De Backer G, Degaute JP. Patient compliance and therapeutic coverage: comparison of amlodipine and slow release nifedipine in the treatment of hypertension. The Belgian Collaborative Study Group. Eur. J. Clin. Pharmacol.47(6), 477–481 (1995).
   PubMed Web of Science ®Google Scholar
• Kruse W, Rampier J, Ullrich G, Weber E. Patterns of drug compliance with medications to be taken once and twice daily assessed by continuous electronic monitoring in primary care. Int. J. Clin. Pharmacol. Ther.32(9), 452–457 (1994).
   PubMed Web of Science ®Google Scholar
• Rubenfire M and IMPACT of Medical Subspecialty on Patient Compliance to Treatment Study Group. Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study. Am. J. Cardiol.94(3), 306–311 (2004).
   PubMed Web of Science ®Google Scholar
• Tanabe K, Serruys P, Grube E et al. TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in slow-release polymer formulation. Circulation107(4), 559–564 (2003).
   PubMed Web of Science ®Google Scholar
• Waeber B, Erne P, Saxenhofer H, Heynen G. Use of drugs with more than a twenty-four-h duration of action. J. Hypertens. Suppl.12(8), S67–S71 (1994).
   Google Scholar
• Weidler D, Wallin JD, Cook E, Dillard D, Lewin A. Transdermal clonidine as an adjunct to enalapril: an evaluation of efficacy and patient compliance. J. Clin. Pharmacol.32(5), 444–449 (1992).
   Google Scholar
• Cramer JA. Consequences of intermittent treatment for hypertension: the case for medication compliance and persistence. Am. J. Manag. Care4(11), 1563–1568 (1998).
   PubMed Web of Science ®Google Scholar
• National Guidelines Research and Development Unit. Essential hypertension: managing adult patients in primary care. Evidence-Based Clinical Practice Guideline. (2004).
   Google Scholar
• Pearson M. Chronic heart failure: management of chronic heart failure in adults in primary and secondary care. A Clinical Guideline for the NHS in England and Wales (2003).
   Google Scholar
• Dezii C, Kawabata H, Tran M. Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for Type 2 diabetes. South Med. J.95(1), 68–71 (2002).
   PubMed Web of Science ®Google Scholar
• Kardas P. The DIACOM (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of Type 2 diabetes). Diabetes Obes. Metab.7, 722–728 (2005).
   PubMed Web of Science ®Google Scholar
• Mason BJ, Matsuyama JR, Jue SG. Assessment of sulfonylurea adherence and metabolic control. Diabetes Educ.21(1), 52–57 (1995).
   PubMed Web of Science ®Google Scholar
• Paes A, Bakker A, Soe-Agnie C. Impact of dosage frequency on patient compliance. Diabetes Care20(10), 1512–1517 (1997).
   PubMed Web of Science ®Google Scholar
• Pullar T, Bitwell A, Wiles P, Hay A, Feely M. Use of pharmacologic indicator to compare compliance with tablets prescribed to be taken once, twice, or three times daily. Clin. Pharmacol. Ther.44(5), 540–545 (1988).
   PubMed Web of Science ®Google Scholar
• Morris A. Addressing the dosing frequency in diabetes: a simple approach to improving adherence to therapy and clinical outcomes. Diabetes Educ.29(3), 440–453 (2003).
   PubMed Web of Science ®Google Scholar
• Coates P, Ismail I, Luzio S et al. Intranasal insulin: the effects of three dose regimens on postprandial glycaemic profiles in Type II diabetic subjects. Diabet. Med.12(3), 235–239 (1995).
   PubMed Web of Science ®Google Scholar
• Taylor R, Foster B, Kyne-Girebalski D, Vanderpump M. Insulin regimens for the non-insulin dependent: impact on diurnal metabolic state and quality of life. Diabet. Med.11(6), 551–557 (1994).
   Google Scholar
• Del Vecchio L, Villa G, Carraro G et al. Italian study on the treatment of anaemia in chronic dialysis patients switched over to less frequent doses of darbepoetin from human recombinant erythropoietin. G. Ital. Nefrol.21(3), 259–266 (2004).
   PubMedGoogle Scholar
• Locatelli F, Canaud B, Giacardy F, Martin-Malo A, Baker N, Wilson J. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrol. Dial. Transplant.18(2), 362–369 (2003).
   PubMed Web of Science ®Google Scholar
• MacDougall I, Matcham J, Gray S. NESP. Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis. Nephrol. Dial. Transplant.18(3), 576–581 (2003).
   PubMed Web of Science ®Google Scholar
• Vanrenterghem Y, Barany P, Mann J et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int.62(6) 2167–2175 (2002).
   PubMed Web of Science ®Google Scholar
• O’Leary M, Erickson J, Smith C, McDermott C, Horton J, Chancellor M. Effect of controlled-release oxybutynin on neurogenic bladder function in spinal cord injury. J. Spinal Cord Med.26(2), 159–162 (2003).
   PubMed Web of Science ®Google Scholar
• van Kerrebroeck P, Jardin A, Laval KU, van Cangh P. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group. Eur. Urol.37(3), 306–313 (2000).
   PubMed Web of Science ®Google Scholar
• van Kerrebroeck P, Jardin A, Van Cangh P, Laval K, ALFORTI Study Group. Long-term safety and efficacy of once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study. Eur. Urol.41(1), 54–60 (2002).
   Google Scholar
• Michel M. A benefit-risk assessment of extended-release oxybutynin. Drug Saf.25(12), 867–876 (2002).
   PubMed Web of Science ®Google Scholar
• Rovner E, Wein A. Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review. Eur. Urol.41(1), 6–14 (2002).
   PubMed Web of Science ®Google Scholar
• Chue P, Eerdekens M, Augustyns I et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur. Neuropsychopharmacol.15(1), 111–117 (2005).
   PubMed Web of Science ®Google Scholar
• Claxton A, de Klerk E, Parry M, Robinson JM, Schmidt ME. Patient compliance to a new enteric-coated weekly formulation of fluoxetine during continuation treatment of major depressive disorder. J. Clin. Psychiatry61(12), 928–932 (2000).
   Google Scholar
• Cramer J, Vachon L, Desforges C, Sussman N. Dose frequency and dose interval compliance with multiple antiepileptic medications during a controlled clinical trial. Epilepsia36(11), 1111–1117 (1994).
   Google Scholar
• Demyttenaere K, Van Ganse E, Gregoire J, Gaens E, Mesters P. Compliance in depressed patients treated with fluoxetine or amitriptyline. Belgian Compliance Study Group. Int. Clin. Psychopharmacol.13(1), 11–17 (1998).
   PubMed Web of Science ®Google Scholar
• Rickels K, Smith W, Glaudin V, Amsterdam J, Weise C, Setlle G. Comparison of two dosage regimens of fluoxetine in major depression. J. Clin. Psychiatry46(3 Pt 2), 38–41 (1985).
   Google Scholar
• Sachdeo R, Leroy R, Krauss G et al. Tiagabine therapy for complex partial seizures. A dose-frequency study. The Tiagabine Study Group. Arch. Neurol.54(5), 595–601 (1997).
   PubMedGoogle Scholar
• Stein M, Pollack M, Bystritsky A, Kelsey J, Mangano R. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology177(3), 280–288 (2005).
   PubMed Web of Science ®Google Scholar
• Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. JAMA261(22), 3273–3277 (1989). Erratum appears in 262(11), 1472 (1989).
   PubMed Web of Science ®Google Scholar
• Diaz E, Neuse E, Sullivan M, Pearsall H, Woods S. Adherence to conventional and atypical antipsychotics after hospital discharge. J. Clin. Psychiatry65(3), 354–360 (2004).
   PubMed Web of Science ®Google Scholar
• Doughty J, Baker G, Jacoby A, Lavallo V. Compliance and satisfaction with switching from immediate-release to sustained-release formulation of valproate in people with epilepsy. Epilepsy Behav.4(6), 710–716 (2003).
   PubMed Web of Science ®Google Scholar
• Hiratsuka S, Kumano H, Katayama J, Hishinuma T, Yamauchi Y, Mizugaki M. Drug Compliance Scale. II. Psychological factors affecting drug compliance in the department of psychosomatic medicine. J. Pharm. Soc. Japan120(2), 230–237 (2000).
   Google Scholar
• Saletu-Zyhlarz G, Anderer P, Arnold O, Saletu B. Confirmation of the neurophysiologically predicted therapeutic effects of trazodone on its target symptoms depression, anxiety and insomnia by postmarketing clinical studies with a controlled-release formulation in depressed outpatients. Neuropsychobiology48(4), 194–208 (2003).
   PubMed Web of Science ®Google Scholar
• Francis G. Benefit-risk assessment of interferon-β therapy for relapsing multiple sclerosis. Expert Opin. Drug Saf.3(4), 289–303 (2004).
   PubMedGoogle Scholar
• Martinelli Boneschi F, Rovaris M, Capra R, Comi G. Mitoxantrone for multiple sclerosis. Cochrane Database Syst. Rev.4, CD002127 (2006).
   Google Scholar
• Love R, Conley R. Long-acting risperidone injection. Am. J. Health Syst. Pharm.61(17), 1792–1800 (2004).
   PubMed Web of Science ®Google Scholar
• Rickels K. Alprazolam extended-release in panic disorder. Expert Opin. Pharmacother.5(7), 1599–1611 (2004).
   PubMed Web of Science ®Google Scholar
• Weber C JR, Sather M, Mace D. Improving patient compliance through use of single daily dosages. Hosp. Pharm.12(10), 508–510 (1977).
   Google Scholar
• Campion G, Lebsack M, Lookabaugh J, Gordon G, Catalano M. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group. Arthritis Rheum.39(7), 1092–1101 (1996).
   PubMed Web of Science ®Google Scholar
• Lehtinen K, Kaarela K, Makisara P, Holttinen K, Gordin A. Tolerability and efficacy of a slow-release indomethacin tablet in ankylosing spondylitis. Br. J. Rheumatol.23(1), 52–56 (1984).
   PubMedGoogle Scholar
• Molina-Lopez J. Fentiazac in osteoarthritis: comparison of BID and QID regimens. Clin. Ther.5(5), 462–471 (1983).
   Google Scholar
• Trenkwalder C, Collado Seidel V, Kazenwadel J et al. One-year treatment with standard and sustained-release levodpa: appropriate long-term treatment of restless legs syndrome? Mov. Disord.18(10), 1184–1189 (2003).
   PubMed Web of Science ®Google Scholar
• Belcon M, Haynes R, Tugwell P. A critical review of compliance studies in rheumatoid arthritis. Arthritis Rheum.27(11), 1227–1233 (1984).
   PubMed Web of Science ®Google Scholar
• Fischer R. Compliance-oriented prescribing: simplifying drug regimens. J. Fam. Pract.10(3), 427–435 (1980).
   Google Scholar
• Fischer R. Frequency of drug-administration. A prime factor in patient compliance and health care cost. J. Miss. State Med. Assoc.19(9), 161–167 (1978).
   PubMedGoogle Scholar
• Haynes R, Sackett D, Taylor W, Roberts R, Johnson A. Manipulation of the therapeutic regimen to improve compliance: conceptions and misconceptions. Clin. Pharmacol. Ther.22(2), 125 (1977).
   PubMed Web of Science ®Google Scholar
• Iskedjian M, Einarson T, MacKeigan L, Shearn Addis A, Mittmann N, Ilersich A. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin. Ther.24(2), 302–316 (2002).
   PubMed Web of Science ®Google Scholar
• Bass D, Prevo M, Waxman D. Gastrointestinal safety of an extended-release, nondeformable, oral dosage form. Drug Saf.25(14), 1021–1033 (2002).
   PubMed Web of Science ®Google Scholar
• Florence A, Jani P. Novel oral drug formulations. Their potential in modulating adverse effects. Drug Saf.10(3), 233–266 (1994).
   PubMed Web of Science ®Google Scholar
• Cramer M, Saks S. Translating safety, efficacy and compliance into economic value for controlled release dosage forms. Pharmacoeconomics5(6), 482–504, (1994).
   PubMed Web of Science ®Google Scholar
• Shireman TI, Svarstad BL, Sweeney JK. Validity of claims data for long-acting injectable medications. J. Pharmacoepidemiol.7(2), 41–55 (1999).
   Google Scholar